Spero Therapeutics, Inc.
NASDAQ:SPRO
0.725 (USD) • At close April 21, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 47.977 | 96.735 | 48.579 | 18.256 | 9.33 | 4.742 | 3.966 | 1.979 | 0.335 | 0 |
| Cost of Revenue
| 0 | 0.367 | 1.547 | 1.117 | 67.003 | 65.775 | 33.885 | 32.869 | 26.333 | 0.011 |
| Gross Profit
| 47.977 | 96.368 | 47.032 | 17.139 | -57.673 | -61.033 | -29.919 | -30.89 | -25.998 | -0.011 |
| Gross Profit Ratio
| 1 | 0.996 | 0.968 | 0.939 | -6.181 | -12.871 | -7.544 | -15.609 | -77.606 | 0 |
| Reseach & Development Expenses
| 96.757 | 51.44 | 47.593 | 64.526 | 67.003 | 65.775 | 33.885 | 32.869 | 26.333 | 11.125 |
| General & Administrative Expenses
| 23.704 | 25.554 | 36.483 | 41.701 | 21.44 | 15.588 | 12.887 | 10.84 | 7.223 | 2.202 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 23.704 | 25.554 | 36.483 | 41.701 | 21.44 | 15.588 | 12.887 | 10.84 | 7.223 | 2.202 |
| Other Expenses
| 0.877 | -1.74 | -4.93 | -0.395 | 0.833 | -13.405 | 1.144 | -4.367 | 0 | 0.174 |
| Operating Expenses
| 121.338 | 75.254 | 79.146 | 106.227 | 88.443 | 67.958 | 42.806 | 41.73 | 33.556 | 13.327 |
| Operating Income
| -73.361 | 21.481 | -42.197 | -87.971 | -79.113 | -63.216 | -42.806 | -41.73 | -33.221 | -13.327 |
| Operating Income Ratio
| -1.529 | 0.222 | -0.869 | -4.819 | -8.479 | -13.331 | -10.793 | -21.086 | -99.167 | 0 |
| Total Other Income Expenses Net
| 4.795 | 3.923 | -4.218 | -1.785 | 0.833 | 2.291 | 1.144 | 1.844 | 0.58 | 0.174 |
| Income Before Tax
| -68.566 | 25.404 | -46.415 | -89.756 | -78.28 | -60.925 | -41.662 | -46.097 | -32.641 | -13.153 |
| Income Before Tax Ratio
| -1.429 | 0.263 | -0.955 | -4.917 | -8.39 | -12.848 | -10.505 | -23.293 | -97.436 | 0 |
| Income Tax Expense
| 0 | 2.598 | 1.613 | 1.545 | -0.761 | -0.75 | 1.144 | -0.363 | -7.73 | -3.173 |
| Net Income
| -68.566 | 22.806 | -48.028 | -91.301 | -77.519 | -60.175 | -41.662 | -46.097 | -25.491 | -10.154 |
| Net Income Ratio
| -1.429 | 0.236 | -0.989 | -5.001 | -8.309 | -12.69 | -10.505 | -23.293 | -76.093 | 0 |
| EPS
| -1.27 | 0.43 | -1.28 | -2.96 | -3.46 | -3.31 | -2.6 | -17.82 | -3.86 | -1.54 |
| EPS Diluted
| -1.27 | 0.43 | -1.28 | -2.96 | -3.46 | -3.31 | -2.6 | -17.82 | -3.86 | -1.54 |
| EBITDA
| -72.482 | 25.771 | -42.263 | -87.17 | -76.934 | -62.466 | -42.397 | -41.367 | -32.942 | -13.316 |
| EBITDA Ratio
| -1.511 | 0.266 | -0.87 | -4.775 | -8.246 | -13.173 | -10.69 | -20.903 | -98.334 | 0 |